Spiroxasone

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Spiroxasone
Spiroxasone.png
Clinical data
Routes of
administration		Oral
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC24H34O3S
Molar mass402.593 g/mol g·mol−1
3D model (JSmol)

Spiroxasone (INN, USAN) is a synthetic, steroidal antimineralocorticoid of the spirolactone group which was developed as a diuretic and antihypertensive agent but was never marketed.[1][2] It was synthesized and assayed in 1963.[1] The drug is 7α-acetylthiospirolactone with the ketone group removed from the C17α spirolactone ring.[1] Similarly to other spirolactones like spironolactone, spiroxasone also possesses antiandrogen activity.[3][4]

References[edit]

  1. ^ a b c J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1114–. ISBN 978-1-4757-2085-3.
  2. ^ I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 261–. ISBN 978-94-011-4439-1.
  3. ^ Progress in Medicinal Chemistry. Elsevier. 1 January 1979. pp. 69–. ISBN 978-0-08-086264-4. Spiroxasone [...] is also an anti-androgen [379].
  4. ^ Rasmusson GH, Chen A, Reynolds GF, Patanelli DJ, Patchett AA, Arth GE (1972). "Antiandrogens. 2',3' -Tetrahydrofuran-2'spiro-17-(1,2 -methylene-4-androsten-3-ones)". J. Med. Chem. 15 (11): 1165–8. PMID 4654667.



Retrieved from "https://en.wikipedia.org/w/index.php?title=Spiroxasone&oldid=817170069"